Previous 10 | Next 10 |
2023-12-07 15:00:49 ET More on BlackRock MuniYield Fund Dividend scorecard for BlackRock MuniYield Fund For further details see: BlackRock MuniYield declares $0.0001 dividend
SALT LAKE CITY, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has delivered results to one million consumers with its SneakPeek ® Early Gender DNA Test . Since 2015, SneakPeek has b...
SALT LAKE CITY and FREMONT, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. , a leader in advanced genomics for precision oncology, (Nasdaq: PSNL) today announced a non-exclusi...
Today, the Board of Directors/Trustees of the BlackRock municipal closed-end funds listed below (the “Funds”) announced distributions, which reflect distribution increases for several Funds. The distribution increases ranged between 29% and 64%. In addition, the Funds declared their...
BlackRock Advisors, LLC (“BlackRock”) will host a conference call on Monday, November 13, 2023 at 11:00am ET to discuss year-end tax loss selling opportunities in the closed-end fund market. The call will feature Russ Koesterich, Portfolio Manager for BlackRock ESG Capital Alloc...
SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will participate in the Stephens Annual Investment Conference in Nashville, TN with a fireside chat on Wednesday, Nov...
SALT LAKE CITY, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) (the “Company” or “Myriad Genetics”), a leader in genetic testing and precision medicine, today announced the pricing of an upsized underwritten public offering of 6,470,588 shares o...
SALT LAKE CITY, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) (the “Company” or “Myriad Genetics”), a leader in genetic testing and precision medicine, today announced that it plans to make a public offering of $100.0 million of shares of its c...
Highlights: Third quarter testing volume grew 18% year-over-year, excluding contributions from the SneakPeek ® Early Gender DNA Test, the fifth consecutive quarter of double-digit year-over-year growth. In the third quarter and year-to-date: ...
Certain BlackRock closed-end funds (the “Funds”) announced distributions today as detailed below. BlackRock Science and Technology Term Trust (NYSE: BSTZ), BlackRock Health Sciences Term Trust (NYSE: BMEZ) and BlackRock Innovation and Growth Term Trust (NYSE: BIGZ) pay month...
News, Short Squeeze, Breakout and More Instantly...
Blackrock MuniYield Fund Inc. Company Name:
MYD Stock Symbol:
NYSE Market:
Blackrock MuniYield Fund Inc. Website:
SALT LAKE CITY, July 31, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Jennifer Fox as Chief Legal Officer, effective September 3, 2024. Fox brings nearly two decades of legal experi...
SALT LAKE CITY, July 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its second quarter earnings conference call on Tuesday, August 6, 2024 at 4:30pm ET. The company’s quarterly earnings will be released ...
SALT LAKE CITY, July 17, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced results from its nationwide Cancer Risk Survey: Breast Cancer Edition , which revealed that a majority (63%) of women do not know th...